CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.